Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) had its target price increased by Noble Financial from $16.00 to $20.00 in a research note issued to investors on Wednesday. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on CRBP. Cantor Fitzgerald set a $24.00 price objective on shares of Corbus Pharmaceuticals Holdings and gave the company a buy rating in a research note on Wednesday, August 9th. BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a strong sell rating to a sell rating in a research note on Friday, August 25th. Finally, ValuEngine downgraded shares of Corbus Pharmaceuticals Holdings from a hold rating to a sell rating in a research note on Wednesday, September 13th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $20.75.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded up $0.20 during midday trading on Wednesday, hitting $7.25. 936,400 shares of the stock were exchanged, compared to its average volume of 811,531. Corbus Pharmaceuticals Holdings has a one year low of $5.30 and a one year high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The company had revenue of $0.80 million during the quarter. sell-side analysts forecast that Corbus Pharmaceuticals Holdings will post -0.63 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/noble-financial-raises-corbus-pharmaceuticals-holdings-inc-crbp-price-target-to-20-00/1696250.html.

A number of institutional investors and hedge funds have recently bought and sold shares of CRBP. State Street Corp increased its position in Corbus Pharmaceuticals Holdings by 2,998.2% during the 2nd quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock worth $3,708,000 after purchasing an additional 569,662 shares in the last quarter. Northern Trust Corp increased its position in Corbus Pharmaceuticals Holdings by 814.3% during the 2nd quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock worth $3,039,000 after purchasing an additional 429,584 shares in the last quarter. Vanguard Group Inc. increased its position in Corbus Pharmaceuticals Holdings by 24.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after purchasing an additional 307,979 shares in the last quarter. Artal Group S.A. acquired a new stake in Corbus Pharmaceuticals Holdings during the 2nd quarter worth approximately $1,575,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in Corbus Pharmaceuticals Holdings during the 2nd quarter worth approximately $760,000. 29.09% of the stock is owned by hedge funds and other institutional investors.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.